Sale to Vectura Group

Activaero Shareholders

Our Frankfurt, London, and New York attorneys advised the shareholders of Activaero GmbH, Gmünden in the sale of all their shares to Vectura Group plc for a total of €130 million, funded through a combination of cash payments and Vectura shares.

Activaero is a private German pharmaceutical company originating from Helmholtz Zentrum München and providing novel solutions for severe respiratory diseases. Vectura is a UK-based product development company, listed on the London Stock Exchange (LSE: VEC), which focuses on the development of pharmaceutical therapies for the treatment of airways-related diseases. The acquisition of Activaero fulfills a number of strategic priorities for Vectura in a single transaction, including making the company a therapeutic area specialist for airways diseases.

Email Disclaimer